3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
22
Prostatic Neoplasms, Castration-Resistant
4
Non-metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Hormone-sensitive Prostate Cancer
2
Male Urogenital Diseases
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Non-Metastatic
1
Non-metastatic Prostate Cancer
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
High-Risk Localized Prostate Cancer
1
Healthy Volunteers
1
Genital Diseases, Male
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Advanced Solid Tumor
1
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostate Cancer Non-Metastatic
×
darolutamide
×
Clear all
NCT02200614
2022-06-28
ARAMIS
Bayer
Phase 3
Completed
1,509 enrolled
13 charts
1 FDA